Description

Incyte Corporation is a biopharmaceutical entity dedicated to the discovery, development, and global commercialization of its proprietary therapeutic innovations. Its portfolio features established medications such as JAKAFI, prescribed for the treatment of myelofibrosis and polycythemia vera. Another key offering is PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor designed to target oncogenic drivers found in various liquid and solid tumor types. Additionally, ICLUSIG serves as a kinase inhibitor to address chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Incyte also maintains a robust clinical pipeline, advancing several candidates through different development stages. This includes ruxolitinib, currently being investigated for steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III clinical trials for patients with naïve chronic GVHD. Pemigatinib is another promising asset, targeting bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and showing potential as a tumor-agnostic treatment. Furthermore, Parsaclisib is in Phase II clinical trials for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. The company is also developing Retifanlimab, an asset in Phase II trials for MSI-high endometrial cancer, Merkel cell carcinoma, and anal cancer, with additional Phase II studies underway for non-small cell lung cancer. Beyond its internal programs, Incyte actively engages in strategic alliances with numerous industry partners. These collaborations involve entities such as Novartis International Pharmaceutical Ltd., Eli Lilly and Company, Agenus Inc., Calithera Biosciences, Inc., MacroGenics, Inc., Merus N.V., Syros Pharmaceuticals, Inc., Innovent Biologics, Inc., Zai Lab Limited, Cellenkos, Inc., and Nimble Therapeutics. Notably, it also pursues clinical collaborations with MorphoSys AG and Xencor, Inc. to explore the combined efficacy of tafasitamab, plamotamab, and lenalidomide in patients battling relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the company's corporate headquarters are located in Wilmington, Delaware.